Pfizer plans to acquire Trillium Therapeutics for $2.26B

By The Science Advisory Board staff writers

August 23, 2021 -- Pfizer plans to acquire immuno-oncology drug developer Trillium Therapeutics for $2.26 billion in a deal that will expand Pfizer's portfolio to include immunotherapeutics for blood diseases.

Trillium's biologics are designed to help the immune system of patients identify and destroy cancer cells, Pfizer said. Its two lead candidates include the signal-regulatory protein alpha fragment crystallizable region (SIRPα-Fc) fusion proteins TTI-622 and TTI-621, which block the key immune checkpoint SIRPα-CD47 axis. The molecules are currently in phase IB/II development.

The move comes almost a year after Pfizer invested $25 million in Trillium as part of its Pfizer Breakthrough Growth Initiative, which offers scientific research funding and access to Pfizer's experts, it said.


Copyright © 2021 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.